NetworkNewsBreaks – Akers Biosciences, Inc. (NASDAQ: AKER) Receives Initial Order for Cholesterol Test from First Check; Shares Surge

Shares of Akers Biosciences (NASDAQ: AKER) climbed 71% on news of the company receiving an initial order for its rapid cholesterol self-test from First Check Diagnostics, LLC, the exclusive distributor for this product in the United States, for sale under its popular “First Check” brand. Akers’ Tri-Cholesterol “Check” test provides an estimate of a person’s total cholesterol as well as his or her high density lipoprotein cholesterol levels, or ‘good cholesterol’. This provides the user with an estimate of his or her low density lipoprotein levels, or ‘bad cholesterol’, making it an effective screening test for high cholesterol. “I am delighted that we will soon have this over-the-counter health and wellness product from Akers Bio on the shelves of major US retailers under the distinguished First Check brand. It is a great endorsement of our rapid testing technology. We look forward to building this revenue stream with our distribution partner and providing people in America with a fast, convenient and meaningful way to evaluate and manage their cholesterol, which is a serious concern for millions of people,” Akers CEO John J. Gormally stated in the news release.

To view the full press release, visit:

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the company and its products can be found at

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s